Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s Disease: A placebo-controlled, randomized and double blind clinical trial.
New treatments were presented for management of Alzheimer’s Disease (AD) in the recent years. However, they were not fully successful. The objective of this study was to assess the efficacy and safety of Salvia officinalis extract in AD at 4 months using fixed dose of the extract. A randomized, doub...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Institue of Medicinal Plants, ACECR
2002-09-01
|
| Series: | Journal of Medicinal Plants |
| Subjects: | |
| Online Access: | http://jmp.ir/article-1-801-en.html |
| _version_ | 1818902965091565568 |
|---|---|
| author | Sh Akhondzadeh M Norouzian MR Mohammadi S Ohadinia AH Jamshidi M Khani |
| author_facet | Sh Akhondzadeh M Norouzian MR Mohammadi S Ohadinia AH Jamshidi M Khani |
| author_sort | Sh Akhondzadeh |
| collection | DOAJ |
| description | New treatments were presented for management of Alzheimer’s Disease (AD) in the recent years. However, they were not fully successful. The objective of this study was to assess the efficacy and safety of Salvia officinalis extract in AD at 4 months using fixed dose of the extract. A randomized, double blind, placebo-controlled trial in three centers in Iran was the structure of this study. Patients with mild to moderate AD (n=36, 10 women) with a score of ≤ 12 on the cognitive subscale of Alzheimer’s Disease Assessment (ADAS-cog) and ≤ 2 on Clinical Dementia Rating (CDR) were randomized to placebo or fixed dose of Salvia officinalis extract. Over 16 weeks, the primary outcome measure was the change in ADAS-cog score. Change in CDR (sum of the boxes) was the secondary outcome over the trial. At 4 months, Salvia extract produced a significant better outcome on cognitive function and CDR total score than placebo (ADAS-cog: d.f.: 1 f = 4.77, P = 0.037) (CDR: d.f.: 1, F=10.84, P<0.003). There were no significant differences in the two groups in terms of observed side effects. The present study indicates that patients on Salvia officinalis extract compare with those on placebo experienced benefits in cognitive function and basic activity of daily living. However, further studies are warranted. |
| first_indexed | 2024-12-19T20:44:01Z |
| format | Article |
| id | doaj.art-34d340b3c27f4a9a86d3d135835fe15e |
| institution | Directory Open Access Journal |
| issn | 2717-204X 2717-2058 |
| language | English |
| last_indexed | 2024-12-19T20:44:01Z |
| publishDate | 2002-09-01 |
| publisher | Institue of Medicinal Plants, ACECR |
| record_format | Article |
| series | Journal of Medicinal Plants |
| spelling | doaj.art-34d340b3c27f4a9a86d3d135835fe15e2022-12-21T20:06:18ZengInstitue of Medicinal Plants, ACECRJournal of Medicinal Plants2717-204X2717-20582002-09-01133343Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s Disease: A placebo-controlled, randomized and double blind clinical trial.Sh Akhondzadeh0M Norouzian1MR Mohammadi2S Ohadinia3AH Jamshidi4M Khani5 Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran Institute of Medicinal Plants, Tehran, Iran Institute of Medicinal Plants, Tehran, Iran New treatments were presented for management of Alzheimer’s Disease (AD) in the recent years. However, they were not fully successful. The objective of this study was to assess the efficacy and safety of Salvia officinalis extract in AD at 4 months using fixed dose of the extract. A randomized, double blind, placebo-controlled trial in three centers in Iran was the structure of this study. Patients with mild to moderate AD (n=36, 10 women) with a score of ≤ 12 on the cognitive subscale of Alzheimer’s Disease Assessment (ADAS-cog) and ≤ 2 on Clinical Dementia Rating (CDR) were randomized to placebo or fixed dose of Salvia officinalis extract. Over 16 weeks, the primary outcome measure was the change in ADAS-cog score. Change in CDR (sum of the boxes) was the secondary outcome over the trial. At 4 months, Salvia extract produced a significant better outcome on cognitive function and CDR total score than placebo (ADAS-cog: d.f.: 1 f = 4.77, P = 0.037) (CDR: d.f.: 1, F=10.84, P<0.003). There were no significant differences in the two groups in terms of observed side effects. The present study indicates that patients on Salvia officinalis extract compare with those on placebo experienced benefits in cognitive function and basic activity of daily living. However, further studies are warranted.http://jmp.ir/article-1-801-en.htmlkeywords: dementiaalzheimer’s diseasetraditional medicinesalvia officinalis |
| spellingShingle | Sh Akhondzadeh M Norouzian MR Mohammadi S Ohadinia AH Jamshidi M Khani Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s Disease: A placebo-controlled, randomized and double blind clinical trial. Journal of Medicinal Plants keywords: dementia alzheimer’s disease traditional medicine salvia officinalis |
| title | Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s Disease: A placebo-controlled, randomized and double blind clinical trial. |
| title_full | Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s Disease: A placebo-controlled, randomized and double blind clinical trial. |
| title_fullStr | Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s Disease: A placebo-controlled, randomized and double blind clinical trial. |
| title_full_unstemmed | Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s Disease: A placebo-controlled, randomized and double blind clinical trial. |
| title_short | Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s Disease: A placebo-controlled, randomized and double blind clinical trial. |
| title_sort | salvia officinalis extract in the treatment of mild to moderate alzheimer s disease a placebo controlled randomized and double blind clinical trial |
| topic | keywords: dementia alzheimer’s disease traditional medicine salvia officinalis |
| url | http://jmp.ir/article-1-801-en.html |
| work_keys_str_mv | AT shakhondzadeh salviaofficinalisextractinthetreatmentofmildtomoderatealzheimersdiseaseaplacebocontrolledrandomizedanddoubleblindclinicaltrial AT mnorouzian salviaofficinalisextractinthetreatmentofmildtomoderatealzheimersdiseaseaplacebocontrolledrandomizedanddoubleblindclinicaltrial AT mrmohammadi salviaofficinalisextractinthetreatmentofmildtomoderatealzheimersdiseaseaplacebocontrolledrandomizedanddoubleblindclinicaltrial AT sohadinia salviaofficinalisextractinthetreatmentofmildtomoderatealzheimersdiseaseaplacebocontrolledrandomizedanddoubleblindclinicaltrial AT ahjamshidi salviaofficinalisextractinthetreatmentofmildtomoderatealzheimersdiseaseaplacebocontrolledrandomizedanddoubleblindclinicaltrial AT mkhani salviaofficinalisextractinthetreatmentofmildtomoderatealzheimersdiseaseaplacebocontrolledrandomizedanddoubleblindclinicaltrial |